NL-OMON40094撤回不适用
A Feasibility Trial to Evaluate the Senseonics Continuous Glucose Monitoring System - The Senseonics CGM-System Feasibility Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Females and males aged >=18 to <=65 years of age.
- •2. Clinically confirmed diagnosis of Type 1 diabetes mellitus (for at least 1 year of duration)
- •on multiple daily injections (>2 injections per day) or on insulin pump therapy.
- •3. HbA1c <=10%.
- •4. Subject understands study procedures and risks, is willing to comply with protocol
- •requirements, and has signed an informed consent document.
排除标准
- •Subjects will be denied participation in the investigation if they meet any of the following key,
- •exclusion criteria:
- •1. History of severe hypoglycemia in the 6 months immediately prior to study start.
- •2. Severe diabetic Ketoacidosis in the past 6 months.
- •3. Females who are lactating, pregnant or intending to become pregnant during the course
- •of the investigation, defined as
- •3.1 Not postmenopausal for at least 1 year OR
- •3.2 Not surgically sterile, OR
- •3.3 If of child bearing potential, the subject is not practicing birth control, not willing to
- •avoid pregnancy for the period of study participation, has a positive serum pregnancy test
- •at screening or has a positive urine pregnancy test at the time of the Sensor insertion
- •4. Any condition preventing or complicating the placement, operation or removal of the
- •Sensor, including but not limited to:
- •4.1 Upper extremity deformities that would impede the placement of the Sensor or
- •application of the external Reader.
- •4.2 Any skin condition that may affect Sensor insertion or external Reader placement.
- •5. Any medical condition or illness that in the judgment of the investigator might interfere
- •with the procedures, results or compliance during the course of this investigation, or
- •increase the risk of induced hypoglycemia or repeated blood testing, including but not
- •limited to:
- •5.1 Anemia, defined as either:
- •5.1.1 Hemoglobin (Hgb) value for females of < 12.0 g/dl, for males < 13.0 g/dl OR
- •5.1.2 Abnormal red cell indices and iron deficiency.
- •5.2 History of hepatitis B, hepatitis C or HIV.
- •5.3 Symptomatic coronary artery disease, unstable angina, myocardial infarction or stroke
- •within 6 months of screening, uncontrolled hypertension, or congestive heart failure.
- •5.4 Any seizure disorder.
- •5.5 History of adrenal insufficiency.
- •5.6 Significantly impaired hepatic function
- •5.7 Renal failure, defined as any prior dialysis or an estimated glomerular filtration rate
- •(eGFR) below 60 mL/min per 1.73 m2 using CKD-EPI formula (Levey et al, 2009)
- •6. Known microvascular (diabetic) complications (other than non-proliferative retinopathy),
- •including active proliferative diabetic retinopathy or macular edema, non-proliferative
- •retinopathy stage 3, diabetic nephropathy (other than microalbuminuria with normal
- •creatinine), gastroparesis or neuropathy requiring treatment.
- •7. Currently receiving any of the following therapies, or likely to need such treatment during
- •the follow-up period of this study:
- •7.1 Immunosuppressant therapy
- •7.2 Chemotherapy for any form of cancer
- •7.3 Anti-coagulant therapy (e.g. Plavix, LMW heparin, coumadin)
- •7.4. Chronic systemic glucocorticoids (excluding topical, optical or nasal, but including
- •7.5. Antibiotic treatment for chronic infection (e.g. osteomyelitis)
- •8. Magnesium <1.6 mg/dL at screening.
- •9. Potassium <3.4 mmol/L at screening.
- •10. Hematocrit >50% or <30% at screening.
- •11. Topical or local anesthetic allergy.
- •12. Known current or recent alcohol or drug abuse by subject history.
- •13. Participation in another clinical investigation within 30 days preceding screening, or
- •intention to participate in any other clinical investigation during the period of this study.
- •14. The presence of any other active implanted device, whether turned on or off. Passive
- 另有 1 项未显示
研究者
相似试验
招募中
不适用
A Feasibility Trial to Evaluate the Senseonics Continuous Glucose Monitoring SystemCTRI/2013/12/004204Senseonics Inc20
进行中（未招募）
Unknown
A feasibility study to evaluate a digital intervention for treating unipolar depression in adultsTreatment of unipolar depression in patients on the waiting list for outpatient psychotherapeutic treatmentMental and Behavioural DisordersISRCTN18035062Elona Health GmbH40
已完成
不适用
Feasibility study for the development of a sensorimotor insole for postnatal activation of the pelvic floorN39.3Stress incontinenceDRKS00008030Zürcher Hochschule für Angewandte Wissenschaften20
已完成
2 期
Proof of Concept Test on the efficacy of ultrasonography contrast agent perflurubutane in the differential diagnosis of nodular thyroid lesionsodular thyroid lesions(bening and malignant)JPRN-UMIN000020905Gunma University Hospital department of nuclear medecine10
已完成
不适用
A non-therapeutic feasibility study to evaluate the kinetics and test-retest repeatability and reproducibility of the radioligand [11C]-UCB-J for imaging synaptic density in healthy subjects and mild-to-moderate Alzheimer*s Disease subjectsdementiaAlzheimerAlzheimer's DiseaseNL-OMON48549Rodin Therapeutics, Inc.20